As a result, efforts are underway to test the effects of inhibiting antiapoptotic proteins in additional cancer types, particularly in combination with other small-molecule treatments such as DNA-damaging agents or compounds that target PI3K/mTOR signaling (20, 31–34). The gene discussed is PIK3CA; the disease is cancer.